ArticleCancer management and research2025
The Role of AHCY Expression in Bladder Urothelial Carcinoma: A Bioinformatics and Experimental Analysis.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated bulk and single-cell transcriptomics unveil the role of AHCY in cell cycle regulation of endometrial cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although adenosylhomocysteinase (AHCY) is crucial to the oncogenesis and growth of some cancers, it is unknown how this affects bladder urothelial carcinoma (BLCA). Investigating the variations in AHCY expression in BLCA and examining the relationship between AHCY expression and BLCA patient prognosis were the goals of this investigation. Methods: By leveraging The Cancer Genome Atlas (TCGA) database, we undertook a meticulous examination of AHCY expression levels, juxtaposing them between BLCA and normal tissues. Subsequently, Kaplan-Meier analysis and COX regression and nomogram was used to assess the effect of AHCY on the survival of BLCA patients. We further elaborated on the possible enriched pathways of AHCY and its immune relevance. In addition, we employed si-RNA technology to downregulate the AHCY gene expression and subsequently utilized quantitative real-time PCR (qRT-PCR), CCK-8, cell scratch assays, and Transwell migration assays to validate the pivotal role of AHCY in BLCA. Results: The expression of AHCY was associated with various types of malignancies (including BCLA). In BLCA cancer tissues, there was an observed upregulation of AHCY expression in comparison to paracancerous tissues. Increased expression of AHCY was linked to decreased overall survival (OS), clinical stage, N stage, and T stage in individuals with BLCA. The functional enrichment of AHCY related genes mainly involves biological processes such as rRNA metabolic processes, proteasome activity, and cell cycle regulation, etc. Furthermore, AHCY showed significant associations with m6A related genes and infiltration of immune cells (Especially for Th2 cells and T-gd lymphocytes). In vitro functional experiments substantiated that the inhibition of AHCY effectively suppresses the growth, migration, and invasion of bladder cancer cells. Conclusion: This study provides novel insights into the role of AHCY in BLCA, which holds significant potential to contribute towards advancing the diagnosis and treatment of BLCA in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.